A polymorphism of the GTP-cyclohydrolase i feedback regulator gene alters transcriptional activity and may affect response to SSRI antidepressants

Pharmacogenomics Journal

Volumn 11, Issue 3, 2011, Pages 207-213

  McHugh, P C ^a,b   Joyce, P R ^a   Deng, X ^a   Kennedy, M A ^a  

^a UNIVERSITY OF OTAGO   (New Zealand)

^b University of Bath   (United Kingdom)

Author keywords

neurotransmitters; pharmacogenetics; SSRIs; tetrahydrobiopterin

Indexed keywords

CITALOPRAM; FLUOXETINE; GUANOSINE TRIPHOSPHATE CYCLOHYDROLASE I FEEDBACK REGULATOR; MEMBRANE PROTEIN; NORTRIPTYLINE; PAROXETINE; UNCLASSIFIED DRUG;

3' UNTRANSLATED REGION; 5' UNTRANSLATED REGION; ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DNA SEQUENCE; ENZYME REGULATION; EXON; FEMALE; GENE LINKAGE DISEQUILIBRIUM; GENETIC VARIABILITY; GFRP GENE; HAPLOTYPE; HOMOZYGOSITY; HUMAN; INTRON; MAJOR DEPRESSION; MALE; MULTIPLE REGRESSION; NEUROTRANSMISSION; OPEN READING FRAME; PHENOTYPE; PRIORITY JOURNAL; PROMOTER REGION; RANDOMIZED CONTROLLED TRIAL; REGULATOR GENE; SINGLE NUCLEOTIDE POLYMORPHISM;

ADULT; ANTIDEPRESSIVE AGENTS; BIOPTERIN; CLINICAL TRIALS AS TOPIC; FEMALE; FLUOXETINE; GENETIC ASSOCIATION STUDIES; HAPLOTYPES; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; MOOD DISORDERS; NORTRIPTYLINE; POLYMORPHISM, SINGLE NUCLEOTIDE; PROMOTER REGIONS, GENETIC; SEROTONIN; SEROTONIN UPTAKE INHIBITORS; TRANSCRIPTIONAL ACTIVATION;

EID: 79957514956     PISSN: 1470269X     EISSN: 14731150     Source Type: Journal    
DOI: 10.1038/tpj.2010.23     Document Type: Article

References (30)

1. Nagatsu T, Ichinose H. Regulation of pteridine-requiring enzymes by the cofactor tetrahydrobiopterin. Mol Neurobiol 1999; 19: 79-96. (Pubitemid 29174242)
2. Ohue T, Koshimura K, Lee K, Watanabe Y, Miwa S. A novel action of 6R-L-erythro-5,6,7,8-tetrahydrobiopterin, a cofactor for hydroxylases of phenylalanine, tyrosine and tryptophan: enhancement of acetylcho-line release in vivo in the rat hippocampus. Neurosci Lett 1991; 128: 93-96.
3. Miwa S, Watanabe Y, Koshimura K, Masaki T. [A novel function of tetrahydrobiopterin]. Nippon Yakurigaku Zasshi 1992; 100: 367-381. (Pubitemid 23010881)
4. McHugh PC, Joyce PR, Kennedy MR. Polymorphisms of sepiapterin reductase gene alter promoter activity and may influence risk of bipolar disorder. Pharmacogenet Genomics 2009; 19: 330-337.
5. Curtius HC, Niederwieser A, Levine RA, Lovenberg W, Woggon B, Angst J. Successful treatment of depression with tetrahydrobiopterin. Lancet 1983; 1: 657-658. (Pubitemid 13152368)
6. Miura H, Qiao H, Kitagami T, Ohta T. Fluvoxamine, a selective serotonin reuptake inhibitor, suppresses tetrahydrobiopterin in the mouse hippocampus. Neuropharmacology 2004; 46: 340-348. (Pubitemid 38223867)
7. Miura H, Kitagami T, Ozaki N. Suppressive effect of paroxetine, a selective serotonin uptake inhibitor, on tetrahydrobiopterin levels and dopamine as well as serotonin turnover in the mesoprefrontal system of mice. Synapse 2007; 61: 698-706. (Pubitemid 47122741)
8. Hashimoto R, Nagatsu T, Ohta T, Mizutani M, Omura I. Changes in the concentrations of tetrahydrobiopterin, the cofactor of tyrosine hydro-xylase, in blood under physical stress and in depression. Ann NY Acad Sci 2004; 1018: 378-386. (Pubitemid 38951431)
9. Hashimoto R, Mizutani M, Ohta T, Nakazawa K, Nagatsu T. Changes in plasma tetrahydrobiopterin levels of depressives in depressive and remission phases: reconfirmed by measurement with an internal standard. Neuropsychobiology 1994; 29: 57-60. (Pubitemid 24052080)
10. Abou-Saleh MT, Anderson DN, Collins J, Hughes K, Cattell RJ, Hamon CG et al. The role of pterins in depression and the effects of antidepressive therapy. Biol Psychiatry 1995; 38: 458-463.
11. McQuillin A, Rizig M, Gurling HM. A microarray gene expression study of the molecular pharmacology of lithium carbonate on mouse brain mRNA to understand the neurobiology of mood stabilization and treatment of bipolar affective disorder. Pharmacogenet Genomics 2007; 17: 605-617. (Pubitemid 47057710)
12. McHugh PC, Rogers GR, Loudon B, Glubb DM, Joyce PR, Kennedy MA. Proteomic analysis of embryonic stem cell-derived neural cells exposed to the antidepressant paroxetine. J Neurosci Res 2008; 86: 306-316. (Pubitemid 351196736)
13. Brandish PE, Su M, Holder DJ, Hodor P, Szumiloski J, Kleinhanz RR et al. Regulation of gene expression by lithium and depletion of inositol in slices of adult rat cortex. Neuron 2005; 45: 861-872. (Pubitemid 40395265)
14. Harada T, Kagamiyama H, Hatakeyama K. Feedback regulation mechanisms for the control of GTP cyclohydrolase I activity. Science 1993; 260: 1507-1510. (Pubitemid 23273265)
15. Kapatos G, Hirayama K, Shimoji M, Milstien S. GTP cyclohydrolase I feedback regulatory protein is expressed in serotonin neurons and regulates tetrahydrobiopterin biosynthesis. J Neurochem 1999; 72: 669-675. (Pubitemid 29055229)
16. Yoneyama T, Wilson LM, Hatakeyama K. GTP cyclohydrolase I feedback regulatory protein-dependent and -independent inhibitors of GTP cyclohydrolase I. Arch Biochem Biophys 2001; 388: 67-73. (Pubitemid 32911564)
17. Ciulla TA, Sklar RM, Hauser SL. A simple method for DNA purification from peripheral blood. Anal Biochem 1988; 174: 485-488.
18. Thony B, Auerbach G, Blau N. Tetrahydrobiopterin biosynthesis, regeneration and functions. Biochem J 2000; 347(Part 1): 1-16. (Pubitemid 30199034)
19. McHugh PC, Joyce PR, Kennedy MA. Polymorphisms of sepiapterin reductase gene alter promoter activity and may influence risk of bipolar disorder. Pharmacogenet Genomics 2009; 19: 330-337.
20. White LA, Eaton MJ, Castro MC, Klose KJ, Globus MY, Shaw G et al. Distinct regulatory pathways control neurofilament expression and neurotransmitter synthesis in immortalized serotonergic neurons. J Neurosci 1994; 14: 6744-6753. (Pubitemid 24333092)
21. Joyce PR, Mulder RT, Luty SE, Sullivan PF, McKenzie JM, Abbott RM et al. Patterns and predictors of remission, response and recovery in major depression treated with fluoxetine or nortriptyline. Aust NZ J Psychiatry 2002; 36: 384-391. (Pubitemid 34777988)
22. Spitzer RL, Williams JB, Gibbon M, First MB. The Structured Clinical Interview for DSM-III-R (SCID). I: history, rationale, and description. Arch Gen Psychiatry 1992; 49: 624-629.
23. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960; 23: 56-62.
24. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry 1979; 134: 382-389. (Pubitemid 9136500)
25. Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E et al. The Mini-International Neuropsychiatric Interview (MINI): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry 1998; 59(Suppl 20): 22-33; quiz 34-57. (Pubitemid 29001829)
26. Steinberg M. Interviewers Guide to the Structured Clinical Interview for DSM-IV Dissociative Disorders (SCID-D). American Psychiatric Press: Washington, DC, 1994.
27. Hirschfeld RM, Williams JB, Spitzer RL, Calabrese JR, Flynn L, Keck Jr PE et al. Development and validation of a screening instrument for bipolar spectrum disorder: the Mood Disorder Questionnaire. Am J Psychiatry 2000; 157: 1873-1875.
28. Light KJ, Joyce PR, Luty SE, Mulder RT, Frampton CM, Joyce LR et al. Preliminary evidence for an association between a dopamine D3 receptor gene variant and obsessive-compulsive personality disorder in patients with major depression. Am J Med Genet B Neuropsychiatr Genet 2006; 141: 409-413. (Pubitemid 43872895)
29. Shi YY, He L. SHEsis, a powerful software platform for analyses of linkage disequilibrium, haplotype construction, and genetic association at polymorphism loci. Cell Res 2005; 15: 97-98. (Pubitemid 41653949)
30. Briley M, Moret C. Neurobiological mechanisms involved in antide-pressant therapies. Clin Neuropharmacol 1993; 16: 387-400. (Pubitemid 23292094)